Iterum Therapeutics Plc (ITRM) Tops Q2 EPS by 15c

Iterum Therapeutics Plc (NASDAQ: ITRM) reported Q2 EPS of ($0.30), $0.15 better than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Iterum Therapeutics Plc (ITRM) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• CrowdStrike (CRWD) PT Lowered to $227 at Scotiabank
• H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)